Literature DB >> 17000097

Elevated BALF concentrations of alpha- and beta-defensins in patients with pulmonary alveolar proteinosis.

Hiroshi Mukae1, Hiroshi Ishimoto, Shigehisa Yanagi, Hiroshi Ishii, Seiko Nakayama, Jun-Ichi Ashitani, Masamitsu Nakazato, Shigeru Kohno.   

Abstract

Defensins are endogenous antibiotics and regulators of inflammation, immunity and wound repair. Their concentrations are substantially increased in bronchoalveolar lavage fluid (BALF) of patients with infectious lung diseases. alpha-defensin (HAD) levels are also elevated in patients with idiopathic pulmonary fibrosis (IPF) and correlated with the decline in pulmonary function tests, suggesting the association of defensins with the pathogenesis of interstitial lung diseases. The aim of this study was to determine the profile of defensins in interstitial lung diseases. Serum and BALF levels of HAD and beta-defensin 1 and 2 (HBD-1, and -2) were measured by radioimmunoassay in 63 patients with interstitial lung diseases, including idiopathic pulmonary alveolar proteinosis (PAP), IPF, nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) and pulmonary sarcoidosis, and in 9 healthy volunteers as controls. Levels of HAD in BALF of patients with PAP were significantly higher than those in controls and patients with COP and sarcoidosis. Serum levels of HAD in all groups were significantly higher than those in controls. Levels of HBD-1 and -2 in BALF of patients with PAP were extremely high in all subjects. Serum levels of HBD-1 were higher in all patient groups, with the exception of those with PAP, and those of HBD-2 were also higher in patients with IPF and sarcoidosis, compared with controls. BALF of PAP patients, but not IPF patients and controls, expressed antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus. Our findings suggest different kinetics of HAD and HBD-1 and -2 in serum and BALF of interstitial lung diseases and that these antimicrobial peptides in the airway lumen may contribute to prevention of bacterial airway infections in PAP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000097     DOI: 10.1016/j.rmed.2006.08.018

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Kazuhisa Konishi; Kevin F Gibson; Kathleen O Lindell; Thomas J Richards; Yingze Zhang; Rajiv Dhir; Michelle Bisceglia; Sebastien Gilbert; Samuel A Yousem; Jin Woo Song; Dong Soon Kim; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2009-04-10       Impact factor: 21.405

Review 2.  Host defense peptides in the oral cavity and the lung: similarities and differences.

Authors:  G Diamond; N Beckloff; L K Ryan
Journal:  J Dent Res       Date:  2008-10       Impact factor: 6.116

3.  Dysregulation of human beta-defensin-3 expression in the peripheral blood of patients with sepsis.

Authors:  Noura Al Mansour; Ghada Al-Kafaji; Ali Al Mahmeed; Khalid M Bindayna
Journal:  SAGE Open Med       Date:  2021-08-23

4.  Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier.

Authors:  Khalil Bdeir; Abd Al-Roof Higazi; Irina Kulikovskaya; Melpo Christofidou-Solomidou; Sergei A Vinogradov; Timothy C Allen; Steven Idell; Rose Linzmeier; Tomas Ganz; Douglas B Cines
Journal:  Am J Respir Crit Care Med       Date:  2010-01-21       Impact factor: 21.405

5.  Immunohistochemical study on the distribution of β-defensin 1 and β-defensin 2 throughout the respiratory tract of healthy rats.

Authors:  Natsumi Masuda; Youhei Mantani; Hideto Yuasa; Chiaki Yoshitomi; Masaya Arai; Miho Nishida; Wang-Mei Qi; Junichi Kawano; Toshifumi Yokoyama; Nobuhiko Hoshi; Hiroshi Kitagawa
Journal:  J Vet Med Sci       Date:  2018-01-01       Impact factor: 1.267

6.  Elevated α-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease.

Authors:  Noriho Sakamoto; Hiroshi Ishimoto; Tomoyuki Kakugawa; Minoru Satoh; Tomoko Hasegawa; Shin Tanaka; Atsuko Hara; Shota Nakashima; Hirokazu Yura; Takuto Miyamura; Hanako Koyama; Towako Morita; Seiko Nakamichi; Yasushi Obase; Yuji Ishimatsu; Hiroshi Mukae
Journal:  BMC Pulm Med       Date:  2018-03-12       Impact factor: 3.317

Review 7.  Defensins and sepsis.

Authors:  Guo-Hao Xie; Qi-Xing Chen; Bao-Li Cheng; Xiang-Ming Fang
Journal:  Biomed Res Int       Date:  2014-08-19       Impact factor: 3.411

8.  Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.

Authors:  Noriho Sakamoto; Tomoyuki Kakugawa; Atsuko Hara; Shota Nakashima; Hirokazu Yura; Tatsuhiko Harada; Hiroshi Ishimoto; Kazuhiro Yatera; Yutaka Kuwatsuka; Toshihide Hara; Kunihiro Ichinose; Yasushi Obase; Yuji Ishimatsu; Shigeru Kohno; Hiroshi Mukae
Journal:  Respir Res       Date:  2015-12-10

9.  Heterozygous Mutations in OAS1 Cause Infantile-Onset Pulmonary Alveolar Proteinosis with Hypogammaglobulinemia.

Authors:  Kazutoshi Cho; Masafumi Yamada; Kazunaga Agematsu; Hirokazu Kanegane; Noriko Miyake; Masahiro Ueki; Takuma Akimoto; Norimoto Kobayashi; Satoru Ikemoto; Mishie Tanino; Atsushi Fujita; Itaru Hayasaka; Satoshi Miyamoto; Mari Tanaka-Kubota; Koh Nakata; Masaaki Shiina; Kazuhiro Ogata; Hisanori Minakami; Naomichi Matsumoto; Tadashi Ariga
Journal:  Am J Hum Genet       Date:  2018-02-15       Impact factor: 11.025

Review 10.  Role of Alarmins in the Pathogenesis of Systemic Sclerosis.

Authors:  Antonello Giovannetti; Elisabetta Straface; Edoardo Rosato; Marco Casciaro; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.